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Key Points: 
• CD37 positivity predicts significantly better survival in DLBCL treated with R-CHOP, 
predominating other prognostic factors in GCB-DLBCL 
• CD37 loss is a potent risk factor for R-CHOP resistance in both GCB- and ABC-DLBCL 
Abstract 
CD37 (tetraspanin TSPAN26) is a B-cell surface antigen widely expressed on mature B-cells. 
CD37 is involved in immune regulation and tumor suppression but its function has not been fully 
elucidated. In this study, we assessed CD37 expression in de novo diffuse large B-cell 
lymphoma (DLBCL), and investigated its clinical and biologic significance in 773 patients treated 
with rituximab-CHOP and 231 patients treated with CHOP chemotherapy. We found CD37 loss 
(CD37−) in ~60% of DLBCL predicted significantly decreased survival rates in R-CHOP-treated 
patients, independent of the International Prognostic Index (IPI), germinal-center-B-cell–like 
(GCB)/activated-B-cell–like (ABC) cell-of-origin, nodal/extranodal primary origin, and the 
prognostic factors associated with CD37−, including TP53 mutation, NF- Bhigh, Mychigh, p-
STAT3high, survivinhigh, p63−, and BCL6 translocation. Conversely, CD37 positivity predicted 
superior survival, abolishing the prognostic impact of high IPI and above biomarkers in GCB-
DLBCL but not in ABC-DLBCL. Combining CD37− status and ABC cell-of-origin risk scores with 
the IPI, defined as M-IPI-R (molecularly-adjusted-IPI-for-R-CHOP), or IPI-plus-
immunohistochemistry for CD37, Myc, and Bcl-2 (defined as IPI+IHC), significantly improved 
risk prediction over IPI alone. Gene expression profiling suggested that decreased CD20 and 
increased PD-1 levels in CD37− DLBCL, ICOSLG upregulation in CD37+ GCB-DLBCL, and 
CD37 functions during rituximab-CHOP treatment, underlie the pivotal role of CD37 signaling to 
clinical outcomes. In conclusion, CD37 is a critical determinant of rituximab-CHOP outcome in 
DLBCL especially in GCB-DLBCL, representing its importance for optimal rituximab action and 
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sustained immune responses. The combined molecular and clinical prognostic indices, M-IPI-R 
and IPI+IHC, have remarkable predictive values in rituximab-CHOP-treated DLBCL.  
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Introduction 
The leukocyte surface antigen CD37 (TSPAN26), a member of the 
tetraspanin/tetraspan/transmembrane-4 superfamily, is widely expressed on normal and 
malignant mature B-cells and downregulated in plasma cells.1-4 Most B-cell malignancies 
express CD37, including B-cell non-Hodgkin lymphoma (NHL) and B-cell chronic lymphocytic 
leukemia (CLL).5 CD37 was detected at variable levels in 60% of Burkitt lymphoma cell lines.6 
Although CD37 expression in neoplastic B-cells correlated with the maturation stage of their 
corresponding B-cell counterparts, B-CLL has lower CD37 levels than do normal mature 
circulating B-lymphocytes.3  
Tetraspanins are considered as “molecular facilitators” of signaling transduction, 
involved in a wide range of biological processes including cell growth, survival, adhesion, 
trafficking, intercellular communication via exosomes, metastasis, and immune responses.1,4,7-9 
CD37 forms complexes with other tetraspanins and major histocompatibility complex (MHC) 
class-II on B-cells. CD37 is important for T-cell–B-cell interaction, IgG/IgA production, and a 
balance between immune responses and tolerance,1,2,4,10-13 although its role in adaptive 
immunity is controversal.1,13-15 Using a Cd37-/- mouse model and a confirmative cohort of 
patients with diffuse large B-cell lymphoma (DLBCL), our study group recently showed that loss 
of CD37 and interaction between CD37 and SOCS3 leads to constitutive activation of the IL6-
AKT-STAT3 pathway, spontaneous development of germinal center-derived lymphoma, and 
poorer clinical outcomes.16  
CD37 could be targeted by monoclonal antibodies in patients with CLL and NHL 
expressing high levels of CD37. Although anti-CD37 antibody development predates rituximab 
(a chimeric monoclonal anti-CD20 IgG1 antibody) by nearly a decade, anti-CD37 antibodies 
(with otlertuzumab/TRU-016 most common) are in the spotlight only recently1,5,17-20 and have 
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shown promise in phase I/II clinical trials for CLL and NHL.1 Upon cross-ligation with anti-CD37 
antibodies, CD37 transduces both death signals (from the N-terminal domain associated with 
SHP1, LYN, and PI3K ) and opposing survival signals (from the C-terminal domain recruiting 
p85 and PI3K ).10  
DLBCL is the most common and heterogeneous NHL. Although the addition of rituximab 
(R-) to CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, Oncovin/vincristine, 
prednisone) significantly improves clinical outcomes, approximately one-third of DLBCL patients 
still have refractory disease or relapse.21-23 Currently, DLBCL risk stratification relies mainly on 
the International Prognostic Index (IPI), which is based on patients’ clinical features. However, 
the IPI cannot identify high-risk subgroups in the rituximab era,24,25 since it was originally 
developed for CHOP outcome prediction from multivariate survival analyses in CHOP-treated 
patients.26 Unfortunately, robust and reproducible biomarkers in DLBCL are also lacking.27,28 
Gene expression profiling (GEP) subdivides DLBCL into two major molecular subtypes, 
germinal-center-B-cell–like (GCB) DLBCL and activated-B-cell–like (ABC) DLBCL, and patients 
with ABC-DLBCL have poorer survival.29 In ABC-DLBCL, B-cell receptor (BCR) signaling is 
chronically active with constitutive activation of antiapoptotic nuclear factor-kappaB (NF- B); 
comparably, GCB-DLBCL has tonic BCR signaling with PI3K pathway activation (either 
proapoptotic or antiapoptotic).30,31 
In this study, we assessed CD37 status and its prognostic effects in large cohorts of 
patients with DLBCL, and correlated CD37 status with tumor biology at both the protein and 
mRNA levels to determine the underlying mechanisms. 
 
Methods  
Patients  
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Totally 1,037 patients with de novo DLBCL were studied as a part of the International 
DLBCL R-CHOP Consortium Program, including 806 R-CHOP-treated patients (discovery 
cohort: n = 560, validation cohort: n = 246) and 231 CHOP-treated patients. The study was 
conducted in accordance with the Helsinki Declaration and was approved as being of minimal or 
no risk or as exempt by the institutional review boards of all participating medical centers.  
Genetic and immunohistochemical analysis 
Tissue microarrays prepared from the diagnostic formalin-fixed, paraffin-embedded 
(FFPE) blocks were stained with a CD37 monoclonal antibody (clone 2B8, Thermo Fisher 
Scientific).16 FFPE tissue sections were also stained for IgA, IgG, IgM, p53, MDM2, p63, NF- B 
subunits, p-STAT3, Myc, Bcl-2, Bcl-6, CD10, GCET1, FOXP1, MUM1/IRF4, BLIMP-1, Ki-67, 
CD5, CD30, CXCR4, PI3K, p-AKT, and survivin, and assessed for TP53 mutations and 
MYC/BCL2/BCL6 translocations, as described in the supplemental materials. GEP was 
performed on Affymetrix GeneChips HG-U133 Plus Version 2.0 (Affymetrix, Santa Clara, CA) 
using total RNAs extracted from FFPE tissues (GSE#31312).32  
Statistical analysis 
Correlations between CD37 and the clinical factors and biomarkers were analyzed using 
the chi-square test, Fisher’s exact test, unpaired t test (2-tailed), and Spearman rank correlation. 
Survival analysis was performed using the Kaplan-Meier method and the log-rank (Cox-Mantel) 
test with GraphPad Prism 6 software. Overall survival (OS) was calculated from the date of 
diagnosis to the date of death from any cause or last follow-up for censored patients. 
Progression-free survival (PFS) was calculated from the date of diagnosis to the date of disease 
progression, recurrence, or death from any cause. Multivariate analysis was conducted using 
Cox proportional hazard regression models with SPSS software, version 19.0 (IBM, Armonk, 
NY). P values 0.05 were considered statistically significant. 
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Results 
DLBCL patients with CD37 surface expression have significantly better clinical outcomes 
CD37 surface expression was scored in 5% increments and CD37 staining was 
evaluable for 527 cases in the discovery cohort. Fig. 1A and B show representative CD37-
negative (CD37−) and CD37-positive (CD37+) immunohistochemistry results, respectively. 
Staining for CD37 was positive ( 5%) at variable expression levels in 40% (212/527) of the 
discovery cohort (Fig. 1C). The ABC-DLBCL subgroup had a higher frequency of CD37+ 
patients than the GCB-DLBCL subgroup (46.8% vs. 33.6%, Table 1), and a higher mean level of 
CD37 protein (P = .002; Figure 1D) and CD37 mRNA (P < .0001; Supplemental Figure S1A). 
Cell-of-origin according to the B-cell-associated gene signatures classification33 did not show 
significant differences between the CD37+ and CD37– groups, although in the GCB subtype, 
CD37+ DLBCL had a nonsignificantly higher frequency of centrocyte cell-of-origin (Supplemental 
Figure S1B). 
At clinical presentation, patients with CD37– DLBCL had a higher frequency of ECOG 
performance status >1 than patients with CD37+ DLBCL (20.6% vs. 10.7%, Table 1). Although 
the CD37+ DLBCL group had a trend toward more elderly ( 60 years) patients (P = .064), these 
patients had a significantly higher complete response rate and significantly increased OS and 
PFS rates compared with the CD37– DLBCL patients (P < .0001; Figure 1E). The favorable 
effect of CD37 expression was independent of GCB/ABC subtype, high/low IPI, and 
nodal/extranodal primary origin (Figures 1F-H). Among the CD37+ patients, CD37 high/low 
levels did not seem to be prognostic, although in some CD37+ ABC-DLBCL patients with high 
CD37 levels, the favorable effect of CD37 expression was decreased (Supplemental Figure 
S1C). The significant impact of CD37+/– status was confirmed in an independent validation 
cohort (n = 246) (P = .0003 for OS and P = .0065 for PFS, Supplemental Figure S1D). 
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CD37 loss is associated with lower levels of CD37 and CD20 mRNA expression  
CD37 mRNA levels were obtained from the GEP data and correlated with CD37 protein 
levels. The CD37+ group had a significantly higher mean level of CD37 mRNA than the CD37– 
group (Figure 2A). Employing the Spearman rank correlation method, CD37 protein and CD37 
mRNA levels were significantly correlated (r = 0.25, P = 7.57e-8). In addition, CD37 negativity 
was associated with downregulation of many BCR signaling–related genes (Table 2). 
CD20/MS4A1 mRNA levels significantly correlated with both CD37 protein (r = 0.209, P = 
8.16e-6) and CD37 mRNA levels (r = 0.406, P = 3.40e-21), likely reflecting both CD37 and 
CD20 are expressed in mature B-cells with BCR and downregulated in plasma cells. Moreover, 
tested in 13 DLBCL cell lines, CD20 and CD37 protein levels measured by flow cytometry also 
showed significant correlation (Spearman rank correlation: r = 0.771, P = .002). In six cell lines 
(CD20–/CD37–: Oci-Ly19, SU-DHL6, WSU-NHL; CD20+/CD37+: Oci-Ly8, SU-DHL5, and SU-
DHL2), CD20 and CD37 levels showed strong correlation, confirmed by two different CD37 
monoclonal antibodies (WR17, HH1) (linear regression: R2 = 0.9737, Figure 2B). As control, 
CD19 expression was also measured and detected on all DLBCL cell lines. 
We further treated these six cell lines with rituximab (Rituxan and MabThera) and 
compared the cytotoxic effect. As expected, CD20–/CD37–/CD19+ cell lines had less Rituxan-
binding and were resistant to rituximab treatment in contrast to CD20+/CD37+/CD19+ cell lines 
(Figure 2B, Supplemental Figure S2A). Likewise, in the discovery cohort, patients with lower 
(<mean) CD20 mRNA levels had significantly poorer OS and PFS in the overall DLBCL and 
ABC-DLBCL cohorts, and poorer OS in the GCB-DLBCL cohort (Figure 2C).  
In order to investigate whether CD37’s prognostic significance was actually due to its 
association with CD20 mRNA levels, firstly we incorporated both CD20 mRNA and CD37 
factors into the survival analysis (Figures 2D-E, Supplemental Figure S2B). We found CD37+ 
status significantly predicted favorable OS and PFS regardless of high/low CD20 mRNA levels; 
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furthermore, CD37+ DLBCL patients with low CD20 mRNA levels still had significantly better OS 
and PFS than CD37– DLBCL patients with high CD20 mRNA levels, especially in cases of GCB-
DLBCL. On the other hand, CD20 mRNA levels only showed significant impact on OS and PFS 
in CD37– DLBCL overall (but not in the GCB/ABC subset), and on PFS in the CD37+ ABC 
subgroup.  
Secondly, to eliminate the confounding prognostic effects conferred by CD20, we 
studied CD37 expression in a CHOP-treated cohort (n = 231). We found CD37 positivity still 
correlated with significantly better survival, yet with less predictive power (P = .022 for OS and P 
= .013 for PFS), more significantly in GCB-DLBCL than in ABC-DLBCL (Supplemental Figure 
S3A). However, this favorable impact was limited in patients with relatively low CD37 levels 
( 50%) while was lost in CD37high (>50%) patients (Figure 3F). Comparing between CHOP-
treated and R-CHOP-treated patients, CD37high patients especially had improved survival with 
R-CHOP treatment regardless of CD20 mRNA levels (Supplemental Figures S3B-C).  
Together, these results suggest that although CD20 levels may partially contribute to the 
prognostic effects of CD37 status in CD37– DLBCL and CD37+ ABC-DLBCL patients treated 
with R-CHOP, CD37 positivity predicts better survival (more remarkable in GCB-DLBCL), 
independent of CD20 expression, but to certain extent, dependent on the use of rituximab.  
 
CD37 loss in DLBCL is associated with adverse prognostic factors, including TP53 
mutations, NF- B activation, and MYC translocation 
To get a better understanding of the underlying molecular mechanisms, we first 
correlated CD37 status with a spectrum of genetic/phenotypical biomarkers. Compared with the 
CD37+ group, the CD37– group more frequently had GCB cell-of-origin, TP53 mutation, MYC 
rearrangement, increased p50, RelB, and p65 (NF- B) nuclear expression, and the IgA+ 
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immunophenotype. Conversely, the CD37+ group more frequently had ABC cell-of-origin, p63+, 
PI3Khigh, CXCR4high, GCET1high, FOXP1high, MUM1/IRF4high, and the IgM+ immunophenotype. 
 To eliminate the confounding effect of the GCB predominance in CD37– DLBCL on the 
molecular differences, we further compared the CD37– and CD37+ groups in GCB-DLBCL and 
ABC-DLBCL separately. In GCB-DLBCL, CD37– was associated with TP53 mutations and 
nuclear expression of p50, p65, Myc, and p-STAT3. In ABC-DLBCL, CD37– was associated with 
BCL6 translocations and nuclear expression of p50, RelB, and survivin. In contrast, CD37+ 
GCB-DLBCL was associated with GCET1 and BCL-6 expression, and CD37+ ABC-DLBCL was 
associated with PI3K, CXCR4, GCET1, MUM1/IRF4 and FOXP1 expression (Figures 3A-B).  
Predictive value of CD37 expression is robust, especially in GCB-DLBCL 
To examine whether the adverse effect of CD37 loss depends on its associated 
molecular abnormalities and to identify prognostic determinants, we incorporate both CD37 and 
associated biomarkers into the survival analyses. As shown in Figure 3C and Supplemental 
Figure S4A, in GCB-DLBCL, CD37 loss correlated with significantly decreased PFS/OS rates 
with and without TP53 mutation, p50high, p65high, Mychigh, p-STAT3high, GCET1low, BCL-6low, and 
MYC rearrangement, although TP53 mutation, MYC rearrangement, and Mychigh had additive 
adverse effects to CD37 loss. In particular, patients with CD37− GCB-DLBCL without TP53 
mutation, p50high, and Mychigh expression (the 3 adverse factors most strongly associated with 
CD37− in GCB-DLBCL) remained to have significantly worse survival than patients with CD37+ 
GCB-DLBCL (OS: P = .0015; PFS: P = .0011). Conversely, CD37 positivity robustly predicted 
significantly better survival in GCB-DLBCL. In fact, this predictive value completely abolished 
the prognostic significance of TP53 mutation, p50high, Mychigh, p-STAT3high, and GCET1high 
expression in CD37+ GCB-DLBCL, although not that of MYC rearrangement. Even more 
strikingly, the IPI lost prognostic significance in patients with CD37+ GCB-DLBCL (Figure 3D).  
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Similarly, in ABC-DLBCL, CD37 loss predicted significantly worse survival with and 
without p50high, survivinhigh, RelB+, p63–, CXCR4high, PI3Khigh, FOXP1high, MUM1high, and BCL6 
translocations. In particular, patients with CD37− ABC-DLBCL without p50high and survivinhigh 
expression (the two prognostic factors most strongly associated with CD37− in ABC-DLBCL) still 
had significantly poorer survival than patients with CD37+ ABC-DLBCL (OS: P = .0017; PFS: P = 
.0009). However, ABC versus GCB subtype of CD37+ DLBCL patients had significantly worse 
survival (Figure 1F), and among CD37+ ABC-DLBCL patients, high IPI, TP53 mutation, and 
Mychigh had significant adverse impact, in contrast to their lack of apparent effect in patients with 
CD37+ GCB-DLBCL (Figures 3E-F, Supplemental Figure S4B).  
Multivariate survival analysis shows remarkable predictive values of CD37 status in GCB-
DLBCL 
We further performed multivariate survival analysis for CD37–/+ status using Cox 
regression models. After adjustment of clinical variables and CD37 status-associated prognostic 
factors, CD37 status remained to be a significant prognostic factor in overall DLBCL, GCB-
DLBCL and ABC-DLBCL. CD37– status had the most significant risk prediction power among all 
the molecular biomarkers in the Cox model for DLBCL overall (for OS, hazard ratio [HR]: 3.43; 
95% confidence interval [CI]; 1.96-6.02; P < .001; for PFS, HR: 3.91; 95% CI: 2.28-6.71; P < 
.001), followed by ABC cell-of-origin (Table 3).  
Impressively, in patients with GCB-DLBCL, the HR of CD37– was even higher than that 
of IPI >2 (for OS, 4.86 vs. 3.66; for PFS, 5.64 vs. 3.39), and the IPI lost prognostic significance 
in CD37+ GCB-DLBCL (Table 3). Moreover, in both CD37+ and CD37– GCB-DLBCL subsets, all 
biomarkers except Mychigh lost significance as independent factors for poorer survival. 
Differently, in CD37+ ABC-DLBCL, IPI >2, TP53 mutations, Mychigh, p63–, and survivinhigh had 
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significant independent adverse impact, and in CD37– ABC-DLBCL, IPI >2, p50high, p63–, and 
CXCR4high were significant independent adverse prognostic factors (Supplemental Table S1).  
Molecularly-adjusted-IPI-for-R-CHOP significantly improves risk stratification in DLBCL  
Because CD37 status and GCB/ABC cell-of-origin showed remarkable prognostic 
significance independent of the IPI, we tested whether combining these two risk factors with the 
IPI improved the prognostic prediction. The IPI did separate the discovery cohort into four 
groups but had limited power to identify high-risk patients (15.2% of the discovery cohort; P = 
0.073 [OS] and 0.017 [PFS] compared with intermediate-high-risk patients) (Figure 4A). We 
added the scores for CD37 status (add 1 point if CD37–) and cell-of-origin (add 1 point if ABC) to 
the IPI, resulting in a “molecularly adjusted IPI for R-CHOP” (M-IPI-R) score for each patient. 
This “M-IPI-R” could redistribute patients into four groups (low-risk: score 0-1 [16.6%]; 
intermediate-risk: score 2-3 [42.7%]; high-risk: score 4-5 [34.6%]; and very-high-risk: score 6-7 
[6.2%]), and showed significantly improved stratification power compared with the traditional IPI 
and cell-of-origin-adjusted-IPI (Supplemental Figure S5A) scores in separating high-risk and 
very-high-risk patients from intermediate-risk patients (P < .0001) (Figure 4B). The five-year OS 
rates for high-risk and very-high-risk groups were 40.19% and 18.06%, respectively, compared 
to 38.38% for the high-risk group identified by the traditional IPI. 
Within the M-IPI-R-defined risk groups, GCB/ABC was not prognostic anymore but 
CD37– status still showed significant adverse impact (Supplemental Figure S5B). Therefore we 
assigned 1 additional point for CD37– into the “M-IPI-R”, and found neither CD37+/– nor 
GCB/ABC had further prognostic significance within the newly defined risk groups. This version 
of “M-IPI-R”, which may have fully adjusted the risk conferred by CD37–, could refine the 
stratification into 5 different risk groups (Figure 4B): low-risk: score 0-1 (11.5%); low-
intermediate-risk: score 2-3 (33.3%); intermediate-risk: score 4 (20.6%); high-risk: score 5-6 
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(28.7%); and very-high-risk group: score 7-8 (5.9%). The five-year OS rates for the high-risk and 
very-high-risk groups were 37.33% and 19.64%, respectively.  
To develop a more applicable immunohistochemistry-based index, we tested various 
biomarkers and found combining CD37–, Mychigh, and Bcl-2high  risk factors with the IPI, defined 
as “IPI-plus-immunohistochemistry” (IPI+IHC), showed the strongest stratification power without 
redundancy (Supplemental Figure S5C: 1 point for CD37–, and Figure 4C: 3 points for CD37–). 
In Figure 4C, the five-year OS rates for high-risk (score 7-8, 16.3%) and very-high-risk (score 9-
10, 3.5%) groups were 24.21% and 7.81%, respectively. 
GEP analysis suggests roles of CD37 in immune signaling  
We compared gene expression profiles of CD37+ and CD37− groups in the discovery 
DLBCL cohort. Surprisingly, no significant CD37 gene signatures were identified in GCB-DLBCL 
although CD37 status had remarkable prognostic significance. In overall- and ABC-DLBCL only 
weak CD37 signatures were identified (Table 4, Supplemental Table S2), but these signatures 
were also heterogeneously expressed within both the CD37+ and CD37− subgroups (Figure 5A). 
Further gene set enrichment analysis showed that 48 and 125 gene sets were enriched 
in CD37− DLBCL and in CD37− ABC-DLBCL (false discovery rate [FDR] <0.25, Supplemental 
Tables S3-4), respectively, whereas no KEGG pathways were enriched in CD37+ DLBCL or 
CD37+ ABC-DLBCL significantly. Most gene sets enriched in CD37− DLBCL and CD37− ABC-
DLBCL were related to infection (e.g., pertussis, salmonella, Helicobacter pylori, and prion 
disease) and immune signaling, including NOD-like receptor signaling, phagosome, chemokine 
signaling (Figures 5B-C), osteoclast differentiation, TOLL-like receptor signaling, and TNF 
signaling pathway among the top enriched gene sets. 
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Interestingly, a more distinct CD37 gene signature was identified in the PI3Khigh but not 
PI3Klow ABC-DLBCL subset (Figure 5D), suggesting PI3K-involved CD37 signaling in ABC-
DLBCL.10 With  FDR <0.05, 26 genes were upregulated in CD37+/PI3Khigh compared with 
CD37−/PI3Khigh ABC-DLBCL, including BCL11A, PAX5, TCF4, and CLECL1 which functions as 
a T-cell costimulatory molecule. Paradoxically, tumor suppressors EPB41L3 and BCL11B, 
DRAM1 which is critical for p53-mediated apoptosis,34 and SAMSN1 (a negative regulator of B-
cell activation and proliferation) were downregulated in CD37+/PI3Khigh ABC-DLBCL. 
Conversely, 225 genes were upregulated in CD37−/PI3Khigh compared with CD37+/PI3Khigh ABC-
DLBCL, including many related to immune signaling. Of note, CD163 (3.27-fold) is a marker of 
M2 (tumor-promoting) macrophage,35 CD14 (1.53-fold) is a marker for macrophage activation, 
SERPING1 inhibits C1 complex in complement activation, LILRB2 (1.83-fold) encodes a 
leukocyte immunoglobulin-like receptor that negatively regulates MHC-I-mediated antigen 
presentation and immune responses leading to tolerance development,36,37 and CD300A (1.98-
fold) inhibits the antitumor activities by natural killer and mast cells38,39 (Table 4, Supplemental 
Table S5).  
Different from CD37+/− status only showing a weak GEP signature, GCB/ABC cell-of-
origin showed remarkable GEP signatures in both the CD37+ DLBCL and CD37− DLBCL 
subsets (Figures 5E-F): 2346 significant transcripts in CD37+ DLBCL and 1383 transcripts in 
CD37− DLBCL with FDR <0.01 (Table 4: >2 fold difference). In both CD37− and CD37+ DLBCL 
subsets, ABC compared with GCB cell-of-origin had significant upregulation of 
TNFRSF13B/TACI (receptor for TNFSF13/APRIL and TNFSF13B/BAFF), IGHM, CLECL1, 
MIR155HG, IRF4, BATF, and CCL8. Additionally, in the CD37+ subset, ABC- compared with 
GCB-DLBCL had significant upregulation of FOXP1 and AICDA, whereas downregulation of 
HLA-DOB, LRMP (which plays a role in the delivery of peptides to MHC-I), and LMO2. In the 
CD37− subset, ABC compared with GCB cell-of-origin had significant LILRB2 upregulation.   
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CD37 may play important roles in the costimulatory and PD-1 pathways 
 We compared the expression of important immune genes between CD37− and CD37+ 
patients and within the CD37− and CD37+ subsets (Table 5). In GCB-DLBCL, CD37+ status, 
which robustly predicted favorable clinical outcomes, correlated with ICOSLG (encoding 
ICOSL/ICOSLG,40 the ligand for the T-cell-specific receptor ICOS) upregulation, whereas CD37 
loss in ABC-DLBCL correlated with PDCD1/PD-1 upregulation (engagement of PD-1 on T-cells 
with its ligand PD-L1 on tumor cells inhibits T-cell antitumor responses) (Figures 6A-B). In 
p50high DLBCL, CD37− correlated with PD-1 upregulation in both GCB- and ABC-DLBCL (Figure 
6C). Immunohistochemical analysis for PD-1 expression (unpublished preliminary data) further 
confirmed the significant association of CD37 loss with PD-1 overexpression in DLBCL (Figures 
6D-E), with significant or borderline P values in the ABC and GCB subsets.  
ABC versus GCB cell-of-origin correlated with ICOSLG downregulation (P < .0001) and 
IL10RA/IL1041 and LILRB/A upregulation in both CD37− and CD37+ subsets, and with CD274 
and PDCD1LG2 (encoding the PD-1 ligands PD-L1 and PD-L2,42 respectively) upregulation in 
the CD37− subset (also in overall DLBCL) (Figure 6F). Immune dysregulation was also found in 
subsets with TP53 mutations, Mychigh, p50high, p-STAT3high, FOXP1high, MUM1/IRF4high, or 
CXCR4high (e.g., upregulation of PD-L1/L2, CTLA4, TIM3, LILRB2, IL6R, and IL10RB, whereas 
downregulation of ICOSLG, CD58, and MHC-I/II) (Figure 7, Supplemental Figure S6).  
 
Discussion 
 
In this study we demonstrated the robust prognostic value of CD37 status in a large 
cohort of DLBCL. Integrating assessment of CD37 status and GCB/ABC cell-of-origin into the 
IPI calculation (M-IPI-R) markedly improved the predicative power of IPI in R-CHOP-treated 
DLBCL patients. However, currently GCB/ABC classification is not yet the standard of care, 
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although it may be in the future.43 Respecting this, immunohistochemistry for Myc and Bcl-2 
may be an alternative for GCB/ABC determination in the M-IPI-R. 
The pivotal role of CD37+/− status for prognosis has two aspects. First, CD37 positivity is 
an independent predictor of favorable outcome in R-CHOP-treated DLBCL patients. CD37 
ligation experiments have shown that CD37 can function as a death receptor in B-cells.10 Upon 
cross-ligation, CD37 translocates into the membrane lipid rafts, becomes associated with SHP1, 
LYN, and SYK recruiting PI3K , and transduces signaling favoring cellular death.10 Considering 
the somehow R-CHOP-specific but CD20-independent prognostic significance of CD37 
expression (Figure 2), and the lack of a prominent CD37+ GEP signature at diagnosis, we 
speculated that CD37 might act as a “molecular facilitator” of rituximab action during R-CHOP 
treatment, especially for antibody-dependent cellular cytotoxicity, cross-linking, aggregation in 
lipid rafts thereby transactivating tyrosine kinases, apoptosis induction, and long-term T-cell 
responses (Figure 7, I).44-46 Remarkably, such potential CD37-rituximab signaling could abolish 
the adverse impact of many prognostic factors and even that of high IPI scores in GCB-DLBCL, 
but not in ABC-DLBCL however, even though there was no significant difference in CD20 
mRNA levels between GCB-DLBCL and ABC-DLBCL (Supplemental Figure S2B). The 
enhanced antitumor effect by CD37+ might have been dampened in ABC-DLBCL by ICOSLG 
downregulation, and upregulation of TNFRSF13B/TACI, PD-L1, AICDA, IL10/IL10RA, and 
LILRA/B, increased FOXP1 and IRF4 levels which suppress MHC-II expression, chronic active 
BCR signaling, and apoptosis-suppressive mechanisms (e.g., DRAM1, EPB41L3, and BCL11B 
were downregulated in CD37+/PI3Khigh ABC-DLBCL).47,48 Of note, TNFRSF13B/TACI 
suppresses ICOSLG and BIM (proapoptotic) expression.49 
Secondly, CD37 loss independently predicted significantly worse survival in DLBCL. 
Increased PD-1 whereas decreased ICOSLG and CD20 expression,50-56 may contribute to the 
poor clinical outcome of CD37− patients (Figure 7, II). CD20 downregulation could be due to 
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cell-of-origin57,58 of CD37− DLBCL cells or increased cytokines which was reported to suppress 
CD20 expression.59 In addition, many FCGR genes were upregulated in CD37− DLBCL 
especially in p50high/CD37− DLBCL, suggesting the potential for trogocytosis (the transfer of 
rituximab-CD20 complexes from tumor cells to Fc receptor–bearing cells53) and R-CHOP 
resistance. Previous studies have demonstrated that CD37 has a role in T-cell–B-cell interaction 
and humoral responses, which can be observed under suboptimal costimulatory conditions,11 
and that Cd37-/- mice develop germinal center–derived lymphomas.16 In this study, CD37− 
DLBCL was enriched with gene sets related to infection and immune signaling and presence of 
oncogenic drivers, which might result from loss of CD37’s antitumor function during 
lymphomagenesis (potentially also after R-CHOP treatment).  
These results also have therapeutic implications. For CD37+ ABC-DLBCL with higher 
CD37 (but not CD20) expression, anti-CD37 antibody alone or combined with rituximab may 
have higher efficacy. Clinical outcomes may be further improved by combining with BTK 
inhibitors that inhibit BCR and CXCR4 signaling,60 PD-L1 inhibitors, ICOS agonists, and 
immunoregulatory lenalidomide.28,40,61 For CD37− DLBCL with immunosuppressive mechanisms 
and decreased CD20 levels, PD-1 blockade and ICOS agonists may be effective, as well as 
other targeted agents in p50high, Mychigh, p-STAT3high, or ABC subgroups of CD37− DLBCL 
(Figure 7).62,63 Notably, Hodgkin and Reed-Sternberg cells which are thought to originate from 
pro-apoptotic germinal center B-cells but are rescued by acquired survival mechanisms, also 
show loss of CD20, CD37, and BCR and demonstrate particular sensitivity to immune-
checkpoint blockade.64-66  
In summary, in this study we established CD37−/+ status as a robust biomarker and 
introduced two novel prognostic indices, M-IPI-R and IPI+IHC, for risk prediction in R-CHOP-
treated DLBCL. Whether these indices can be useful prognostic tools in the clinic needs to be 
validated by future prospective studies. GEP analysis indicates novel strategies are needed 
19 
especially immunotherapies for CD37− DLBCL and anti-CD37 antibodies for CD37+ ABC-
DLBCL. Our findings from human samples are also valuable for understanding DLBCL 
pathogenesis and heterogeneity and have important clinical implications. 
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Table 1. Comparisons of clinicopathologic characteristics between CD37+ patients and 
CD37− patients with DLBCL, GCB-DLBCL, or ABC-DLBCL 
Variable CD37+ CD37− P CD37+ GCB CD37− GCB P CD37+ ABC CD37− ABC P 
Patients 212 (100%) 315 (100%)  90 (100%) 178 (100%)  118 (100%) 134 (100%) .0023 
Age, years           
< 60 79 (37.3%) 143 (45.4%) .064 42 (46.7%) 89 (50.0%) .90 34 (28.8%) 52 (38.8%) .095 
 60 133 (62.7%) 172 (54.6%)   48 (53.3%) 89 (50.0%) 84 (71.2%) 82 (61.2%) 
Gender           
Female 82 (38.7%) 135 (42.9%) .34 37 (41.1%) 74 (41.6%) .94 43 (36.4%) 60 (44.8%) .18 
Male 130 (61.3%) 180 (57.1%)   53 (58.9%) 104 (58.4%) 75 (63.6%) 74 (55.2%) 
Stage           
I/II 105 (51.5%) 138 (45.0%) .15 53 (61.6%) 88 (50.9%) .10 49 (43.0%) 48 (36.6%) .31 
III/IV 99 (48.5%) 169 (55.0%)   33 (38.4%) 85 (49.1%) 65 (57.0%) 83 (63.4%) 
B-symptoms           
No 132 (66.7%) 193 (63.3%) .44 61 (73.5%) 114 (66.7%) .27 68 (61.3%) 76 (58.0%) .61 
Yes 66 (33.3%) 112 (36.7%)   22 (26.5%) 57 (33.3%) 43 (38.7%) 55 (42.0%) 
LDH level           
Normal 75 (39.1%) 107 (36.8%) .61 34 (43.6%) 65 (39.6%) .56 40 (36.4%) 42 (33.9%) .69 
Elevated 117 (60.9%) 184 (63.2%)   44 (56.4%) 99 (60.4%) 70 (63.6%) 82 (66.1%) 
No. of extranodal sites           
0−1 161 (78.2%) 228 (75.7%) .81 69 (80.2%) 132 (78.1%) .69 89 (76.7%) 93 (72.1%) .41 
 2 45 (21.8%) 73 (24.3%)   17 (19.8%) 37 (21.9%) 27 (23.3%) 36 (27.9%) 
ECOG performance status           
0−1  175 (89.3%) 220 (79.4%) .0044 74 (92.5%) 126 (81.8%) .028 97 (86.6%) 91 (75.8%) .037 
 2 21 (10.7%) 57 (20.6%)   6 (7.5%) 28 (18.2%) 15 (13.4%) 29 (24.2%) 
Size of largest tumor           
< 5cm 98 (60.9%) 131 (56.7%) .41 45 (67.2%) 73 (55.7%) .12 50 (54.9% 58 (59.2%) .56 
 5cm 63 (39.1%) 100 (43.3%)   22 (32.8%) 58 (44.3%) 41 (45.1%) 40 (40.8%) 
IPI score           
0−2 132 (67.3%) 173 (61.3%) .21 64 (78.0%) 106 (66.7%) .07 64 (58.2%) 64 (53.3%) .46 
3−5  64 (32.7%) 109 (38.7%)   18 (22.0%) 53 (33.3%) 46 (41.8%) 56 (46.7%) 
Therapy response*           
CR 189 (89.2%) 215 (68.3%) < .0001 82 (91.1%) 124 (69.7%) < .0001 103 (87.3%) 89 (66.4%) .0001 
PR 18 (8.5%) 52 (16.5%)   6 (6.7%) 25 (14%) 12 (10.2%) 27 (20.1%) 
SD 0 (0%) 23 (7.3%)   0 (0%) 14 (7.9%) 0 (0%) 9 (6.7%) 
PD 5 (2.3%) 25 (7.9%)   2 (2.2%) 15 (8.4%) 3 (2.5%) 9 (6.7%) 
Primary disease       
Extranodal 76 (36.9%) 114 (36.4%) .91 33 (37.5%) 62 (35.2%) .72 40 (35.1%) 51 (38.1%) .63 
Nodal 130 (63.1%) 199 (63.6%) 55 (62.5%) 114 (64.8%) 74 (64.9%) 83 (61.9%) 
IgA IHC           
0% 210 (99.1%) 303 (96.2%) .045 89 (98.9%) 171 (96.1%) .20 117 (99.2%) 129 (96.3%) .13 
100% 2 (0.9%) 12 (3.8%)   1 (1.1%) 7 (3.9%) 1 (0.8%) 5 (3.7%) 
IgG IHC           
0% 189 (89.2%) 283 (89.8%) .80 82 (91.1%) 159 (89.3%) .65 103 (87.3%) 121 (90.3%) .45 
100% 23 (10.8%) 32 (10.2%)   8 (8.9%) 19 (10.7%) 15 (12.7%) 13 (9.7%) 
IgM IHC           
Negative 142 (67.0%) 239 (75.9%) .025 76 (84.4%) 154 (86.5%) .65 63 (52.9%) 82 (61.2%) .19 
Positive 70 (33.0%) 76 (24.1%)   14 (15.6%) 24 (13.5%)  56 (47.1%) 52 (38.8%)  
LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial response; SD, 
stable disease; PD, progressive disease; IHC, immunohistochemistry.  
*We calculated P values as CR vs. other responses. Clinicopathologic data were not available for some cases due to clinical data 
unavailability and tissue exhaustion.  
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Table 2. Differential expression of tetraspanins and B-cell receptor signaling-related 
genes between CD37– and CD37+ patients with GCB- or ABC-DLBCL  
 CD37– vs. CD37+ in GCB/ABC DLBCL  
Genes Downregulation in CD37– Genes Upregulation in CD37– 
CD37  in both GCB (P = .036) and ABC (P < .0001) CD63  in ABC (P < .0001) 
CD20  in both GCB (P = .0008) and ABC (P = .0009) MS4A4A (CD20L1)  in both GCB (P = .0073) and ABC (P = .059) 
CD79A  in both GCB (P = .002) and ABC (P = .009) MS4A6A (CD20L3) Trend of  in ABC (P = .057) 
CD79B  in ABC (P = .032) AKT1  in GCB (P = .019) 
CD22  in both GCB (P = .016) and ABC (P = .011)   
CD23  in GCB (P = .016)   
STAP1  in GCB (P = .0012)   
SWAP70  in GCB (P = .0036)   
SYK  in ABC (P = .045)   
CARD11  in ABC (P = .05)   
BCL10 Trend of  in ABC (P = .07)   
MALT1  in GCB (P = .021)   
CD40  in GCB (P = .016)   
BLNK Trend of  in ABC (P = .064)   
MYC Trend of  in ABC (P = .08)   
REL  in GCB (P = .0031)   
PIK3C2B  in GCB (P = .046) and ABC (P = .07)   
A20/TNFAIP3  in GCB (P = .018) A20/TNFAIP3  in ABC (P = .036) 
The P values were obtained by unpaired t test (2-tailed). 
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Table 3. Multivariate survival analysis for CD37 expression adjusting clinical factors and 
molecular biomarkers associated with CD37+/– in overall DLBCL, GCB-DLBCL, and ABC-
DLBCL, and multivariate analysis in CD37+ GCB-DLBCL 
 Overall Survival  Progression-free survival 
 HR 95% CI P  HR 95% CI P 
In overall DLBCL        
Female sex 0.67 0.42-1.07 0.09  0.74 0.48-1.15 0.18 
B-symptoms 1.68 1.04-2.73 0.035  1.69 1.06-2.68 0.026 
Tumor size 5cm 1.32 0.83-2.09 0.24  1.27 0.82-1.96 0.28 
IPI >2 2.35 1.49-3.70 < 0.001  2.43 1.57-3.75 < 0.001 
ABC subtype 2.12 1.24-3.60 0.006  1.79 1.08-2.98 0.025 
TP53 mutation 1.76 1.05-2.96 0.033  1.68 1.02-2.75 0.040 
p63+ 0.71 0.47-1.07 0.097  0.81 0.55-1.19 0.29 
p50high 1.09 0.70-1.71 0.70  1.13 0.73-1.74 0.58 
CXCR4high 1.81 1.06-3.10 0.03  2.15 1.28-3.63 0.004 
‡CD37+ 0.29 0.17-0.51 < 0.001  0.26 0.15-0.44 < 0.001 
CD37– 3.43 1.96-6.02 < 0.001  3.91 2.28-6.71 < 0.001 
In GCB-DLBCL        
Female sex 0.51 0.26-1.01 0.053  0.57 0.31-1.06 0.075 
B-symptoms 1.27 0.67-2.42 0.46  1.16 0.65-2.10 0.61 
Tumor size 5cm 1.65 0.88-3.08 0.12  1.61 0.91-2.86 0.10 
IPI >2 3.66 1.90-7.01 < 0.001  3.39 1.90-6.06 < 0.001 
TP53 mutation 1.36 0.64-2.89 0.42  1.40 0.70-2.79 0.35 
p50high 0.77 0.35-1.69 0.51  0.71 0.33-1.57 0.40 
p65high 1.90 0.81-4.46 0.14  1.48 0.65-3.36 0.35 
p-STAT3high 0.73 0.28-1.89 0.51  1.20 0.54-2.69 0.65 
MYC–R+ 3.01 1.06-3.98 0.038  2.46 1.03-3.04 0.043 
*Mychigh 2.18 1.14-4.16 0.018  1.67 0.90-3.08 0.10 
‡CD37+ 0.21 0.078-0.54 0.001  0.18 0.073-0.43 < 0.001 
CD37– 4.86 1.84-12.82  0.001  5.64 2.32-13.74 < 0.001 
In ABC-DLBCL        
Female sex 0.86 0.51-1.46 0.58  0.94 0.57-1.55 0.80 
B-symptoms 1.57 0.93-2.66 0.098  1.52 0.91-2.54 0.11 
Tumor size 5cm 1.31 0.77-2.24 0.12  1.18 0.71-1.94 0.53 
IPI >2 2.75 1.65-4.56  < 0.001  2.76 1.58-4.82 < 0.001 
p50high 1.87 1.10-3.16 0.02  1.73 1.07-2.81 0.027 
survivinhigh 1.61 0.89-2.88 0.11  1.47 0.85-2.55 0.17 
CXCR4high 2.17 1.30-3.61 0.003  1.90 1.11-3.24 0.019 
p63+ 0.58 0.34-1.00 0.049  0.62 0.38-1.00 0.048 
‡CD37+ 0.39 0.23-0.67 0.001  0.40 0.23-0.67 0.001 
CD37– 2.57 1.50-4.40 0.001  2.53 1.50-4.44 0.001 
In CD37+ GCB-DLBCL       
Female sex 0.25 0.016-4.08 0.33  0.17 0.014-2.07 0.17 
B-symptoms 2.13 0.17-27.3 0.56  1.59 0.14-17.9 0.71 
Tumor size 5cm 2.61 0.31-22.2 0.38  1.44 0.24-8.62 0.69 
IPI >2 2.08 0.14-30.5 0.60  2.01 0.14-28.0 0.60 
TP53 mutation 1.37 0.095-19.8 0.82  3.17 0.35-28.8 0.31 
Mychigh 20.0 1.87-213.6 0.013  14.1 1.39-143 0.025 
CXCR4high 5.45 0.61-48.7 0.13  6.65 0.85-51.8 0.071 
HR, hazard ratio; CI, confidence interval. The cutoffs for high/positive expression of p50, p65, p-STAT3, Myc, CXCR4, survivin, and p63 were 20%, 
50%, 50%, 70%, 20%, >25%, and >5%, respectively. 
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* Two different Cox regression models were used to include either MYC–R+ or Mychigh as one variant separately. MYC rearrangement was not included 
as a variant in the multivariate analysis in CD37+ GCB-DLBCL because of limited case numbers. 
 Two different models were used to include either CD37+ or CD37– as one variant separately. 
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Table 4. Gene expression profiling analysis between CD37+ and CD37– DLBCL groups 
Function categories Upregulated Downregulated 
 CD37– vs.  CD37+ DLBCL (FDR < 0.05)  
Immune responses, inflammation, host 
defense 
FCGR1B  LILRB2  SERPING1  IRF1  TLR2  
SAMHD1  IFITM1  IFITM3  PYCARD  HEBP1   
 
Signaling FNIP2  RCAN1  SERPINA1   
 
CD37  MS4A1/CD20  VSNL1  LPAR6  
 
Differentiation FNDC3B  AICDA  BCL11A  FOXP1  XBP1  PAX5 
  
 
Gene expression, translation, cell cycle  EIF1  CDK5R1  METTL2A/B  ZNF581  ZNF765 
 
Apoptosis, DNA damage response DRAM1  
 
C9orf102  
Metabolism, protein repair and 
degradation, oxidative stress, lipid 
movement, transport, intracellular 
membrane trafficking 
GCH1  MT1G  MT1P2  PAM  MT1E  C11orf67  
MT1E/MT1H/MT1M  UBR1  APOL6  RCN1  PCMT1 
 MSRB2  NUB1  RAB6A  ARF4  RAB1B  AQP9  
CDIPT  C12orf62  DPYD   
ZDHHC21  GOLGA8A/B  
 
Adhesion, regulation of actin, 
cytoskeleton, exocytosis, and 
extracellular matrix 
RAB27A  AOC3  GPR124  NINJ1  WDR1  
CRISPLD2  RHOU   
 
DMD   
Unknown function, RNA gene  ANKRD22  MOP-1  CNIH4  PLEKHO2  FTHP1  
C4orf32  FAM167B  PWWP2B   
FAM129C  NAPSB  SNORA74A  
BRWD2  FAM108C1  LOC283887  
RAB7L1  LOC133874   
 CD37– vs.  CD37+ ABC-DLBCL (FDR < 0.05)  
Immune responses, inflammation, host 
defense 
LILRB2  C1S  AIF1  IFITM1  IFITM3  SERPING1  
HLA-C  LST1  B2M  ISG15   
 
Signaling SRC  STAT4  CD63  SEMA4D  SECTM1  VDR  
RCAN1  ACVRL1  PREX1  PROCR  TNIP2  RALB 
 
CD37   
 
Differentiation  AICDA  BCL11A  FOXP1  IKZF1  PAX5 
  
Gene expression, translation TCF7L2  EIF4E3  EIF1  C14orf4  KLF3  TBL1XR1  HELLS  RPS2  EBF1  
ZNF587   
Apoptosis, autophagy, DNA repair DRAM1  C19orf40  C9orf102  
Metabolism, ion channel, transport, 
trafficking, protein degradation 
FAM26F  GCH1  MT1P2  MT1E  STOM  
MT1E/MT1H/MT1M  ACSL1  AAK1  VAMP5  RAB13 
 RCN1  RNF217  RAB6A  MGST2  BLVRA  
C14orf133  PDXK  GMPPA  HTATIP2  HEBP1  
CHP1   
C7orf68  GOLGA8B  RIMKLB  DPY19L2 
 UBE3C  DNAJB7    
Adhesion, regulation of actin, 
cytoskeleton, exocytosis, and 
extracellular matrix 
RAB27A  PECAM1  RHOU   MYOF  DYSF  
CCDC80  AOC3  CTNNA1  GPR124   
RALGPS2   
Unknown function, RNA gene ANKRD22  GLIPR2  NKG7  CNIH4  SAMD3  
TMEM176A  SLFN12  PLEKHO2  C21orf33/PWP2  
FAM129C  C13orf18  NAPSB  
SNORA68  SNORA74A  BRWD2  
FAM108C1  SNORD104  FLJ43663  
SNHG12  PMS2L1  LOC284513   
 PI3Khigh/CD37– vs.  PI3Khigh/CD37+ ABC-DLBCL (FDR < 0.01) 
Immune responses, inflammation, host 
defense 
FCGR1B  GBP1  FPR2  TRBC1  IFITM1  FCGR3B 
 FCGR1A/C  C3AR1  CD14   
 
Signaling SECTM1  TNFSF10  SEMA4D  APLP2    
Differentiation, transcription factors BCL11B  KLF3   
Cell cycle CCND1  PTP4A2   
Apoptosis DRAM1  EPB41L3   
Ion channel, transport, trafficking, protein 
degradation, metabolism 
MT1H  FAM26F  MT1G  MT2A  MT1X  CPD  
MT1E/MT1H/MT1M  SLC8A1  MT1E  AAK1  LYST  
APOL6  RAB1A    
 
Adhesion PECAM1   
RNA regulation, unknown function ANKRD22  ZC3H12C  GLIPR2  SNORD104  
 
 CD37– ABC vs.  CD37– GCB (FDR < 0.01, fold change >2) 
Immune responses, inflammation TNFRSF13B  S100A8  GZMB  CLECL1  LILRB2  
FCRL5  CCL8   
IGHG1  
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Signaling IGHM    MME  STAP1  
Transcription regulation, DNA replication, 
microRNA 
BATF  IRF4  MIR155HG   MYBL1  ELL3/SERINC4  STAG3  
SSBP2  BCL6  
Metabolism, ion channel FUT8  FAM26F  DHRS9    
Adhesion, cytoskeleton, extracellular 
matrix 
TUBB4  CD44   CILP  KANK1  PCDHGB7  MARCKSL1  
Unknown function ANKRD22  C1orf186 C13orf18  MPEG1  
 
FLJ42418  C17orf99  TMEM108  TEX9   
CRNDE  CCDC85A  BTNL9  KIAA0746  
 CD37+ ABC vs. CD37+ GCB (FDR < 0.01, fold change >2.18) 
Immune responses TNFRSF13B  CLECL1  FCRL5  GZMB  IGHG1  HLA-DOB  LRMP  CXCL14   
Signaling IGHM  BLNK  MME  STAP1  PTPRS  SPRED2  
PDE4D  RRAS2  FNDC1  
Differentiation AICDA   LMO2  
Transcription regulation, DNA replication, 
microRNA 
FOXP1  PARP15  BATF  TCF4  IRF4  MIR155HG  MYBL1  STAG3  HOPX TOX  SSBP2  
REL  
Cell cycle  NEK6  
Metabolism, transport XK  P2RX5  FUT8  SLC2A13  SLC12A8  PLEKHF2  GALNT14  SULF1 
 LHPP  
Adhesion, cytoskeleton, extracellular 
matrix, migration 
TUBB4   
 
CILP  POSTN  MARCKSL1  DPT  
PCDHGB7  RAPH1  CPNE3  COL5A1  
KANK1  PTK2  
Unknown function C13orf18  FAM129C  C1orf186  TBC1D27  MPEG1 
 
C17orf99  FLJ42418  CCDC144B  
TMEM108  BTNL9  PRO1483  
CCDC85A  KIAA0746  
FDR, false discovery rate. 
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Table 5. Differential expression of genes involved in immune responses or differentiation between 
CD37– and CD37+ patients, between p50high/CD37– and p50low/CD37– patients (CD37– was 
associated with p50high), between CXCR4high/CD37+ and CXCR4low/CD37+ patients (CD37+ was 
associated with CXCR4high in ABC-DLBCL), and between CD37+ ABC-DLBCL and CD37+ GCB-
DLBCL (CD37+ was associated with ABC cell-of-origin) 
 CD37– vs. CD37+ in GCB/ABC 
DLBCL 
p50high vs. p50low  in CD37– 
GCB/ABC DLBCL 
CXCR4high vs. CXCR4low in 
CD37+ GCB/ABC DLBCL 
ABC vs. GCB in 
CD37+ DLBCL 
Genes involved in immune responses or differentiation    
ICOSLG  in GCB (P = .0036)    (P < .0001) 
CD58  in GCB (P = .022)   in CD37+ ABC (P = .056)  (P = .0009) 
FCGR2A (CD32A)  in both GCB (P = .016) and ABC (P = 
.044) 
 in both CD37– GCB (P = .0078) and 
CD37– ABC (P = .016) 
 in CD37+ ABC (P = .02)  (P = .0022) 
FCGR1B (CD64)  in both GCB (P = .01) and ABC (P = 
.0007) 
 in both CD37– GCB (P = .0003) and 
CD37– ABC (P = .0094) 
  (P = .0005) 
C1QB  in both GCB (P = .0001) and ABC (P = 
.0027) 
 in both CD37– GCB (P < .0001) and 
CD37– ABC (P = .0007) 
  (P < .0001) 
CD8A  in ABC (P = .0014)  in both CD37– GCB (P = .017) and 
CD37– ABC (P = .039) 
  
CD8B  in both GCB (P = .068) and in ABC (P = 
.0012) 
 in both CD37– GCB (P = .0059) and 
CD37– ABC (P = .038) 
Trend of  in CD37+ GCB (P 
= .08) and CD37+ ABC (P = 
.068) 
 
PDCD1 (PD-1)  in ABC (P = .03);  in p50high GCB (P = 
.05) 
 in CD37– ABC (P = .03)  in CD37+ GCB (P = .014) 
and trend of  in CD37+ ABC 
(P = .069) 
 
CD274 (PD-L1)   in CD37– GCB (P = .013)  in CD37+ ABC (P = .018)  
PDCD1LG2 (PD-L2) Trend of  in ABC (P = .09)  in CD37– GCB (P = .0025)   
CTLA4   in both CD37– GCB (P = .027) and 
CD37– ABC (P = .0032) 
 in CD37+ ABC (P = .0005) 
trend of  in CD37+ GCB (P = 
.086) 
 
HAVCR2 (TIM3)   in both CD37– GCB (P = .0027) and 
CD37– ABC (P = .0001) 
  
CIITA  in GCB (P = .014)    (P < .0001) 
HLA-A-G  (  in the overall CD37– vs. CD37+ ABC, 
but it is due to the association with p50 
and CXCR4) 
 in both CD37– GCB (P = .0056) and 
CD37– ABC (P = .0003)  
 in both CD37+ GCB (P = 
.0073) and CD37+ ABC (P = 
.025) 
 
LILRB2 (LIR2)  in both GCB (P = .0014) and ABC (P < 
.0001) 
 in both CD37– GCB (P = .0001) and 
CD37– ABC (P = .0065) 
 in CD37+ GCB (P = .0017)  (P < .0001) 
LILRA3 (LIR4)  in ABC (P = .0021)  in CD37– GCB (P = .001)   (P = .0028) 
LILRA1 (LIR6)  in GCB (P = .028)  in CD37– GCB (P = .0062)   (P = .0002) 
CASP1  in ABC (P = .018)  in both CD37– GCB (P = .041) and 
CD37– ABC (P = .029) 
 in CD37+ ABC (P = .0056)  (P = .023) 
CASP7  in GCB (P = .02)  in CD37– ABC (P = .031)   (P < .0001) 
CASP8  in GCB (P = .023)    (P < .0001) 
CASP10  in ABC (P = .018); trends of  in GCB 
(P = .068) 
  in CD37+ GCB (P = .0097)  
CXCL12  in ABC (P = .0072)  in both CD37– GCB (P = .025) and 
CD37– ABC (P = .0007)  
 in CD37+ ABC (P = .0002)   
IL6R   in both CD37– GCB (P = .009) and 
CD37– ABC (P = .0001) 
 in CD37+ ABC (P = .049)  
IL10RB  in ABC (P = .038)  in CD37– GCB (P = .0005)  in CD37+ ABC (P = .034)  
IL21R  in GCB (P = .0036)    
IRF1  in both GCB (P = .025) and ABC (P = 
.0005) 
 in CD37– ABC (P = .0004)   (P = .044) 
STAT1  in ABC (P = .017)  in both CD37– GCB (P = .0068) and 
CD37– ABC (P = .0006) 
  
IFIT3  in both GCB (P = .0071) and ABC (P = 
.0011) 
 in CD37– GCB (P < .0001)  in CD37+ GCB (P = .047)  (P = .011) 
CARD16  in ABC (P = .0022)   in CD37+  ABC (P = .022)  
TCL1A  in ABC (P = .0071) Trend of  in CD37– ABC (P = .076 )  in CD37+ GCB (P = .036)  
AICDA  in ABC (P < .0001)   in both CD37+ GCB (P = 
.028) and CD37+ ABC (P < 
.0001) 
 (P < .0001) 
FOXP1  in ABC (P < .0001)   in CD37+ GCB (P = .03)  (P < .0001) 
BCL11A  in both GCB (P = .0017) and ABC (P < 
.0001)  
 in both CD37– GCB (P = .0058) and 
CD37– ABC (P = .017) 
 in both CD37+ GCB (P = 
.04) and CD37+ ABC (P = 
.0006) 
 
LMO2  in GCB (P = .0007)    (P < .0001) 
POU2F2 (OTF2)  in ABC (P = .0001)    (P < .0001) 
* The cutoffs for p50high and CXCR4high were 20%. The P values were obtained by unpaired t test (2-tailed).  
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Figure Legends 
 
Figure 1. Expression and prognostic effect of CD37 antigen in patients with DLBCL. (A-B) 
Representative CD37 negative and positive (red) immunohistochemistry results (60×). Cell 
nuclei were counterstained with hematoxylin (blue). Images were obtained with an Olympus 
AX70 microscope with a DP71 camera. (C) Histogram of CD37 immunohistochemistry scores in 
the DLBCL discovery cohort. (D) A scatter plot for CD37 expression in DLBCL and comparison 
between GCB and ABC cell-of-origin. (E) Patients with CD37− DLBCL had significantly worse 
OS and PFS compared with patients with CD37+ DLBCL, with a HR of 2.80 and 95% CI of 1.95-
3.38 for OS, and a HR of 2.89 and 95% CI of 2.07-3.45 for PFS. (F-H) The adverse prognostic 
effect of CD37 loss was independent of GCB and ABC cell-of-origin, high and low IPI scores, 
and primary nodal (NL) and primary extranodal (ENL) origin.  
 
Figure 2. CD37 and CD20 expression show correlations but the prognostic significance 
of CD37 is independent of CD20 expression in DLBCL. (A) In both GCB- and ABC-DLBCL, 
the CD37− group had significantly lower mean levels of CD37 and CD20 mRNA expression 
compared with the CD37+ group. (B) Geometric mean fluorescence intensities (gMFI) of CD37 
and CD20 protein expression in 3 different CD37− and 3 different CD37+ DLBCL cell lines 
measured by flow cytometry. CD20 expression on the plasma membrane of DLBCL cells were 
detected by a non-therpeutic CD20 antibody (2H7, BioLegend)  (left), and by therapeutic 
Rutuxan (Roche) (right). Results are representative for 2 independent experiments. Coefficient 
for linear regression: R2 = 0.9737 (Left) and R2 = 0.8043 (right). Dotted lines show 95% 
confidence interval. (C) Low CD20 mRNA expression (< mean) correlated with significantly 
worse OS and PFS, especially in ABC-DLBCL. (D) However, CD37+ patients with lower CD20 
mRNA levels had significantly better OS and PFS than CD37− patients with higher CD20 mRNA 
levels. (E) In GCB-DLBCL, CD37 antigen status but not CD20 mRNA levels predicted survival. 
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In ABC-DLBCL, CD37 status and CD20 mRNA levels showed prognostic impact independent of 
each other, but CD37 status showed stronger prognostic impact. (F) In an independent CHOP-
treated DLBCL cohort, overall CD37+ patients had significantly better PFS than CD37− patients. 
However, the favorable impact was limited in patients with low ( 50%) CD37 levels and patients 
with high (>50%) CD37 expression showed similar PFS with CD37− patients.  
 
Figure 3. Correlation analysis and the robust prognostic effect of CD37 expression in 
patients with DLBCL. (A) A distribution plot showing that CD37− GCB-DLBCL (denoted by the 
yellow bar) more frequently had TP53 mutations (highlighted in red) or high levels of nuclear 
p50 (yellow), Myc (green), phosphorylated STAT3 (orange) and p65 (lighter red) expression 
compared with CD37+ GCB-DLBCL (denoted by the blue bar). (B) A distribution plot showing 
that CD37− ABC-DLBCL more frequently had high nuclear p50 (yellow) and survivin (pink) 
expression and BCL6 translocation (green), whereas CD37+ ABC-DLBCL more frequently had 
PI3K (blue) and CXCR4 (purple) overexpression. Each column in parts A and B represents one 
patient; cases without indicated abnormalities detected are shown in light blue (negative) or 
white (unknown). (C) In GCB-DLBCL, CD37 positivity predicted significantly improved survival, 
regardless of presence of TP53 mutations, p50high, Mychigh, p-STAT3high, GCET1high, and to less 
extent, MYC translocations. Conversely, the adverse effect of CD37 negativity was independent 
of all these biomarkers. Particularly, CD37− patients without TP53 mutations and p50/Myc 
overexpression remained to have significantly worse survival than patients with CD37+ GCB-
DLBCL. (D) In GCB-DLBCL, CD37 positivity predicted significantly better survival even when 
the patients had high IPI scores. (E) In ABC-DLBCL, the adverse prognostic effect of CD37 
negativity was independent of p50, survivin, p63, PI3K, and CXCR4 expression and BCL6 
translocations. In particular, CD37− patients without p50 and survivin overexpression remained 
to have significantly worse survival than patients with CD37+ ABC-DLBCL. (F) In ABC-DLBCL, 
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CD37 and IPI had independent prognostic impact. The cutoffs for high/positive expression as 
indicated by p50+, Myc+, p-STAT3+, GCET1+, survivin+, p63+, PI3K+, and CXCR4+ in the figures 
were 20%, 70%, 50%, 50%, >25%, >5%, 70%, and 20%, respectively. 
 
Figure 4. Comparison of risk stratification in patients with DLBCL by the traditional IPI 
and adjusted IPI scores. (A) Risk stratification of DLBCL groups by the traditional IPI. (B) Risk 
stratification of DLBCL by the molecularly adjusted IPI for R-CHOP (“M-IPI-R”), defined by each 
patient’s IPI score plus risk scores for CD37 status (CD37+: 0; CD37−: 1 or 2 as indicated) and 
GCB/ABC cell-of-origin (GCB: 0; ABC: 1). (C) Risk stratification of DLBCL by the IPI plus 
immunohistochemistry (“IPI+IHC”), defined by each patient’s IPI score plus risk scores for CD37 
status (CD37+: 0; CD37−: 3), and Myc and Bcl-2 protein levels (low [IHC <70%]: 0; high [IHC 
70%]: 1).  
 
Figure 5. Gene expression profiling (GEP) analysis in DLBCL. (A) Heatmap for GEP 
comparison between CD37+ and CD37− DLBCL (FDR <0.05). (B) The KEGG chemokine 
signaling pathway gene set was enriched in the CD37− DLBCL group with an enrichment score 
of 0.45 (FDR: 0.09). (C) The KEGG phagosome gene set was enriched in CD37− ABC-DLBCL 
with an enrichment score of 0.55 (FDR: 0.006). (D) Heatmap for GEP comparison between 
CD37+ ABC-DLBCL and CD37− ABC-DLBCL groups with high ( 70%) PI3K expression (FDR 
<0.01). (E) Heatmap for genes differentially expressed between GCB and ABC subtypes of 
CD37− DLBCL with >2 fold difference (FDR <0.01). (F) Heatmap for genes differentially 
expressed between GCB and ABC subtypes of CD37+ DLBCL with >2.4 fold difference (FDR 
<0.01).  
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Figure 6. Comparison of ICOSL, PDCD1, and PD-1 expression in CD37+ and CD37− 
DLBCL. (A) CD37 positivity was associated with significantly higher levels of ICOSLG in GCB-
DLBCL. (B) CD37 loss correlated with PDCD1 (PD-1) upregulation in ABC-DLBCL. (C) In 
p50high ( 20% nuclear expression) DLBCL, CD37 loss correlated with PD-1 upregulation in both 
GCB- and ABC-DLBCL. (D-E) CD37 loss in DLBCL correlated with significantly higher levels of 
PD-1 receptor expression on both cytotoxic and helper T cells. (F) The ABC subtype had 
significantly higher CD274 (PD-L1) levels compared with the GCB subtype, which was more 
apparent in the CD37− DLBCL subset. 
 
Figure 7. A hypothetic model illustrating the pivotal role of CD37 status for R-CHOP 
outcome in DLBCL and the important molecular mechanisms for R-CHOP resistance in 
CD37− DLBCL and CD37+ ABC-DLBCL.  
(I) CD37 positivity independently predicted favorable outcome, likely because CD37+ DLBCL is 
sensitive to R-CHOP owing to increased CD20 and ICOSLG whereas decreased PD-1 
expression (depicted by green , , and , respectively), as well as CD20-independent CD37 
function in enhancing antibody-dependent cellular cytotoxicity (ADCC) and apoptosis upon 
CD20-rituximab ligation (*). This favorable impact can be hindered by ICOSLG and MHC-II 
downregulation, upregulation of PD-L1, AICDA, LILRA/B, IL10/IL10RA, and antiapoptotic 
pathways downstream of the chronic active B-cell receptor (BCR) signaling in ABC-DLBCL.  
(II)  CD37 loss robustly predicted poor survival. Rituximab efficacy is limited due to decreased 
CD20 levels (depicted by yellow , with postulated reasons of attenuated BCR, cytokine, and 
trogocytosis) and loss of CD37-rituximab signaling. The worse prognosis is also contributed by 
increased PD-1 (highlighted by yellow ), ICOSLG downregulation (highlighted by yellow ), 
and frequent TP53 mutations, Myc, STAT3, or p50 overexpression in CD37− DLBCL (which 
were probably oncogenic drivers acquired during lymphomagenesis and further escaped from 
36 
immune surveillance by various mechanisms as depicted). Illustrated immune escape 
mechanisms includes upregulation of PD-L1/L2, LILRB/A, TIM3, CTLA4, and the IL6/IL10 
pathway, and downregulation of MHC-I/II, CIITA, and costimulatory molecules CD58 and CD40. 
The model is based on our biomarker correlation, GEP, and survival analysis, except the 
speculated CD37 functions during R-CHOP treatment as denoted by “*”. 
 







